StockStory Favors Hims & Hers, Flags Two Healthcare Stocks
The publisher cited improving cash flow at Hims & Hers, while pointing to growth and efficiency concerns at Supernus and Elanco.
Key takeaways
- StockStory highlighted Hims & Hers for expanding free cash flow margin and improving returns on capital.
- The publisher cited slower revenue growth at Supernus and Elanco, along with other financial concerns.
StockStory highlighted Hims & Hers Health as a healthcare stock to watch, while flagging Supernus Pharmaceuticals and Elanco as companies it would pass on. Its assessment cited improving returns on capital and a 15.9-percentage-point expansion in Hims & Hers’ free cash flow margin over five years.
The publisher pointed to Supernus’ 6.5% annual revenue growth over the same period and a 16.5-percentage-point decline in its free cash flow margin. It also noted Elanco’s 2% annual revenue growth and a 3.5-percentage-point drop in adjusted operating margin.
This article was produced with the help of AI technology. Source: Yahoo Finance
